Analysts Shift Focus to 2028 Margin Recovery as Five Upgrades Hit Humana
Five Wall Street firms raised ratings on Humana within about a week after the company reported Q2 2026 results, citing evidence that supports a longer-term margin recovery in the Medicare Advantage business. Price targets now span $370 to $513 versus a share price of $364.46, while InvestingPro's Fair Value of $446 sits near the middle of that rang…